Drug-resistant Tuberculosis Treatment Market size was over USD 1.27 Billion in 2023 and is projected to cross USD 1.90 Billion by the end of 2036, growing at more than 5.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of drug-resistant tuberculosis treatment is evaluated at USD 1.5 Billion.
The growing frequency of tuberculosis cases is driving up the drug-resistant tuberculosis market since it is the deadliest disease among all the other chronic diseases. According to WHO, 10 million people suffer from tuberculosis (TB) disease annually. This disease is preventable and curable but around 1.5 million people die every year from TB. The increasing pressure of tuberculosis in the population raises the requirement for precise diagnostic tests and treatment, which in turn is anticipated to propel the market growth.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
5.2% |
|
Base Year Market Size (2023) |
USD 1.27 Billion |
|
Forecast Year Market Size (2036) |
USD 1.90 Billion |
|
Regional Scope |
|
Treatment (First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs)
First-line anti-TB drugs segment is projected to dominate drug-resistant tuberculosis treatment market share of around 60% by the end of 2036. The segment growth is attributed to FDA approval of medicines, as the developed drug is very effective, and the non-toxic nature of the drug for the treatment of Mycobacterium tuberculosis infections. For new patients, isoniazid, rifampin, pyrazinamide, and one of these - ethambutol or streptomycin, are used. Moreover, these drugs are very effective and can be used with multiple other antibiotics for the treatment of tuberculosis. Moreover, the researchers are focusing on vaccines as this disease is epidemic in some countries.
According to the U.S. Centers for Disease Control and Prevention report 2023, there are particularly 2 types of regimens for tuberculosis treatment - 4-month Rifapentine-moxifloxacin and 6- or 9-month. Further, 4-month Rifapentine moxifloxacin helps in fastening the treatment so that patients may recover early and healthcare staff can look after other patients.
Disease (Active TB, Latent TB)
In drug-resistant tuberculosis treatment market, active TB segment is likely to capture revenue share of over 40% by 2036. Active TB is very harmful since it spreads from one person to another often via air. Moreover, active TB simply means that the germs are growing and impairing tissues present inside the body.
Further, a person is firstly infected by latent TB (primary infection) and afterward by active TB. This happens when the immune system is not resistant to infections. According to a recent report issued in 2022, around 25% of world’s population is infected with TB, out of which 5.8 million were men and 3.5 million women.
Distribution Channel (Hospital, Online Pharmacies, Retail Pharmacies)
By the end of 2036, hospital pharmacies segment is expected to hold drug-resistant tuberculosis treatment market share of over 42%. The segment growth is attributed to instant access to specialized medicines. Both inpatients, outpatients, and in some emergency, cases can easily access these medicines. As per the recent data issued in 2024, there are 685 exporters and 1159 buyers of TB medicines across the world.
Our in-depth analysis of the global market includes the following segments:
|
Treatment |
|
|
Disease |
|
|
Distribution Channel |
|
North American Market Forecast
North America drug-resistant tuberculosis treatment market is poised to capture revenue share of around 35% by the end of 2036. The region has the biggest key players in the market, and the high dominance of respiratory infections is the major factor driving the market growth. According to the Centers for Disease Control and Prevention (CDC) report published in 2022 states that more than 80% of TB cases in the United States were result from long established and untreated latent TB infection.
As per the latest report by the CDC, in 2022, 8331 cases of TB cases were reported in the US i.e., a rate of 2.5 cases per 100,000 persons. Additionally, there are many people living in the region dealing with inactive TB.
Due to the unavailability of appropriate treatment, people in Canada are diagnosed with active TB and in some extreme cases, eventually leading to death. Moreover, immigrants are highly prone to tuberculosis. According to the Canadian Medical Association Journal report issued in 2023, around 0.05% (95% UI 0.04%–0.08%) of foreign-born residents in Canada in 2021 had acquired tuberculosis infection in the preceding 2 years.
APAC Market Analysis
By the end of 2036, Asia Pacific drug-resistant tuberculosis treatment market is estimated to hold over 25% revenue share. The growth is attributed to the strict actions taken by WHO along with UN General Assembly Indonesia to end tuberculosis on a global scale. According to WHO, most of the TB cases in 2021 were recorded in the South-East Asia (45%) region.
China has made huge investments in anti-TB agent research and development leading to the growth of the market. Furthermore, creating awareness among people to take the necessary precautions is important to control the increasing rate of the disease. For instance, Shanghai has implemented TB control measures in China very precisely, but the incidence rate was still above 25/100,000 in 2019.
Indonesia is a low-middle-income country, where TB remains prevalent and healthcare services are inadequate and drug supply is very limited. Furthermore, insufficient information regarding the disease contributes to an increase in TB cases. As per recent data, 969,000 TB cases in Indonesia were recorded in 2021.
The major players in the drug-resistant tuberculosis treatment market are offering a detailed portfolio of tuberculosis related medicines. These companies introduced advanced technologies that enable detailed visualization of test procedures.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?